BioCentury
ARTICLE | Clinical News

Actos pioglitazone: Completed Phase III enrollment

February 22, 2016 8:00 AM UTC

Takeda and Zinfandel (Chapel Hill, N.C.) completed enrollment of about 3,500 patients ages 65-83 in the double-blind, placebo-controlled, international Phase III TOMMORROW trial evaluating 0.8 mg oral...